Advancing the fight against myeloma:
Immunotherapy
T
O INCREASE THE EXCHANGE OF
KNOWLEDGE AND INSIGHTS IN THE
FIELD OF IMMUNO-ONCOLOGY,
the MMRF convened the top minds in cancer
at the “Accelerating the Next Generation of Immune
Treatments in Cancer Summit” in Boston, MA, held in April.
COLLABORATION AND INSIGHTS FROM THE MMRF IMMUNOTHERAPY MEETING
T
he goal of the meeting was to identify ways for all of these groups to form
innovative partnerships to overcome barriers and speed immunotherapy research
so that the best treatments reach cancer patients more quickly. To meet this goal,
the group discussed the need to engage the brightest cancer researchers to answer
important questions around the potential benefits and challenges of immunotherapy.
While the current results of immunotherapy research, clinical trials, and treatments
are very encouraging, many questions remain. For example, the MMRF is seeking
to determine why certain immune approaches benefit some patients but not
others. With the robust investment of the MMRF in immunotherapy and this new
collaborative approach powered by our end-to-end Precision Medicine Model,
proven to accelerate development of new treatments, we are poised to deliver on
the promise of immunotherapy, leading to precisely the right treatments, not only for
myeloma patients but across all cancers.
4
T H E M M R F.ORG